Article

Dawn Holcombe Addresses the Continuing Challenges of Defining Evidence and Value in Oncology

Dawn Holcombe, President of DGH Consulting and Executive Director of the Connecticut Oncology Association, discusses how the increasing demand for data and defining evidence and value are so complex that collaboration between payers and providers is critical.

She also addresses her concern for the viability of the oncology market given the uncertainties of additional changes the federal government may make—especially in an election year—and how such changes could negatively impact the delivery of cancer care.

Related Videos
John Michael O'Brien, PharmD, MPH
Richard J. Nowak, MD, MS, Yale School of Medicine
Naim Alkhouri, MD
Christine Funke, MD
Drs Lillian L. Siu and Matthew G. Vander Heiden
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Benjamin Chen, MD, PhD
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo